相关实验视频

Updated: Jun 4, 2025

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Published on: September 3, 2021

瑞卢戈利克斯通过转化生长因子-β途径减少了瘤细胞外基质的产生

Adina Schwartz¹, Minnie Malik², Paul Driggers²

¹Program in Reproductive Endocrinology and Gynecology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland; Department of Gynecologic Surgery and Obstetrics, Uniformed Services University of the Health Sciences, Bethesda, Maryland.

|December 29, 2024

概括

雷卢戈力克斯是一种口服的GnRH抗剂,可降低瘤细胞对原蛋白和纤维蛋白等细胞外基因蛋白的产生. 这种机制涉及转化生长因子-β (TGF-β) 途径,可能调节子宫纤维瘤大小.

科学领域:

生殖生物学生殖生物学
内分泌学在内分泌学.
细胞和分子医学细胞和分子医学

背景情况:

子宫瘤是常见的良性瘤,其特征是细胞外基质 (ECM) 沉积过多.
转化生长因子-β (TGF-β) 途径与瘤的发病有关,它调节了ECM的产生.
雷卢戈力克斯是一种口服性腺激素释放激素 (GnRH) 抗剂,用于治疗子宫内膜异位症和子宫纤维瘤等疾病.

研究的目的:

为了研究口服GnRH抗剂relugolix对人类乳腺瘤细胞细胞外基质生成的影响.
为了确定relugolix是否通过转化生长因子-β (TGF-β) 信号通路调节leiomyoma ECM的产生.

主要方法:

一项实验室研究,涉及将人类瘤细胞暴露于TGF-β和/或relugolix.
量化TGF-β,酸化的SMAD2/3 (pSMAD2/3),SMAD2/3,原1A1 (COL1A1),纤维素 (FN1) 和素 (VCAN) 的生产情况.
在24小时和48小时后,分析治疗和未治疗的瘤细胞中的蛋白质表达水平.

主要成果:

雷卢戈力克斯治疗导致TGF-β3和pSMAD2/3的产量减少,这种情况与剂量和时间有关.
与relugolix和TGF-β联合治疗相比,与单独使用relugolix相比,显著增加了COL1A1,FN1和VCAN的产生.
这些发现表明,relugolix影响TGF-β通路的关键组成部分和leiomyoma细胞中的ECM合成.

结论:

雷卢戈力克斯通过减少关键ECM组件的产生,包括COL1A1,FN1和VCAN,来调节瘤细胞大小.
观察到的relugolix对ECM产生的影响,至少部分是通过TGF-β信号通路进行介导的.
这些发现为Relugolix如何对子宫纤维瘤施加治疗作用提供了机制性的见解.

关键词:

在Leiomyoma和Leiomyoma之间.在TGF-β的基础上.细胞外矩阵是细胞外矩阵.在Relugolix中使用.

更多相关视频

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

相关概念视频

TGF - β Signaling Pathway

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...